Abstract 420

Triple blockade of the DNAM-axis with COM701 + BMS-986207 + nivolumab demonstrates preliminary antitumor activity in patients with platinum resistant OVCA.

Type: Abstract

Topic: Therapeutic development

Authors: J. Moroney[1], O. Yeku[2], G. Fleming[3], L. Emens[4], D. Vaena[5], E. Dumbrava[6], D. Rasco[7], M. Sharma[8], K. Papadopoulos[9], A. Patnaik[10], R. Sullivan[11], H. Adewoye[12], E. Ophir[13], G. Cojocaru[14], P. Ferre[15], B. Izar[16], S. Gaillard[17]; [1]Dept of Gynecologic Oncology, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, United States of America, [2]Dept of Gynecologic Oncology, MGH - Massachusetts General Hospital, Boston, United States of America, [3]Medical Oncology, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, IL, United States of America, [4]Medicine/Hematology-Oncology Department, UPMC Hillman Cancer Center, Pittsburgh, United States of America, [5]Genitourinary and Phase 1 Programs, West Cancer Center and Research Institute - East Campus, Memphis, United States of America, [6]Investigational Cancer Therapeutics Department, The University of Texas M. D. Anderson Cancer Center, Houston, TX, United States of America, [7]Clinical Research Department, South Texas Accelerated Research Therapeutics (START), San Antonio, United States of America, [8]Medical Oncology Dept., START Midwest, Grand Rapids, United States of America, [9]Clinical Research department, South Texas Accelerated Research Therapeutics (START), San Antonio, TX, United States of America, [10]Medical Oncology Dept., South Texas Accelerated Research Therapeutics (START), San Antonio, United States of America, [11]Medical Oncology, MGH - Massachusetts General Hospital, Boston, MA, United States of America, [12]Clinical Development., Compugen USA Inc., South San Francisco, United States of America, [13]Research and Drug Discovery, Compugen Ltd., Holon, Israel, [14]Biology, Compugen Ltd., Holon, Israel, [15]Preclinical Research, Compugen Ltd., Holon, Israel, [16]630 W 168th Street, William Black Building, Office 1706D, Columbia University, New York, United States of America, [17]Oncology and Gynecology/Obstetrics, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, United States of America

Background

Treatment [tx] options for platinum resistant ovarian cancer [PROC] are limited [ltd]. Immune checkpoint inhibitors (ICI) have ltd activity in PROC. Clinical studies evaluating novel therapies are urgently needed. COM701, a novel, 1st in-class ICI binds to PVRIG, leading to activation of T-cells. BMS-986207 is an ICI blocker of TIGIT. We reported a partial response [PR] with COM701 monotherapy in a pt with primary peritoneal CA[1]. We hypothesized that in pts with PROC, blocking the DNAM axis with the triplet: COM701 + BMS-986207 + nivolumab, would demonstrate antitumor activity with a favorable safety and tolerability profile. We present preliminary results.

Methods

All 20 pts enrolled received COM701 20 mg/kg + BMS-986207 480 mg + nivolumab 480 mg IV Q4W. Primary objectives [obj] were safety/tolerability; secondary obj of antitumor activity. Key inclusion criteria: Age ≥ 18 yrs, histologically confirmed advanced malignancies and exhausted all available standard tx. Key exclusion criteria: prior receipt of any inhibitor of PVRIG, TIGIT, or PD-1/PD-L1. Investigator assessed responses per RECIST v1.1, safety per CTCAE v5.0.

Results

Median [med] age 61yr, med follow-up 51 days [range 1-202], med number of prior lines of therapy - 4 [range 1-10]. Objective response rate 4/20 [20%] pts [all ongoing study tx, 3 confirmed PR], 3 PRs - serous adenoCA, 1 PR - clear cell histology. No complete responses (CR); 4pts with stable disease (SD), disease control rate [CR+PR+SD] 8/20 [40%]. Most frequent [freq] histology - serous adenoCA 10/20 [50%], clear cell 3/20 [15%]. Most freq AE G1/2

fatigue in 11 pts. A sustained immune activation induced by the tx, with a maximum 7.6-fold average increase of peripheral IFNɣ in 16pts evaluated [p<0.005].

Conclusions

The combination of COM701 + BMS-986207 + nivolumab has encouraging signal of antitumor activity with immune activation in pts with heavily pre-treated PROC and is well tolerated. Additional data will be presented at the conference. Data extract 08/29/2022.

1. Vaena D et al, COM701±nivolumab: Results of an ongoing P1 study of safety, tolerability & preliminary antitumor activity in pts with advanced solid malig. J Clin Onco 39, 2021 (suppl 15; abst 2504).

Clinical trial identification

NCT04570839.

Editorial acknowledgement

Print